Team members

Erik van den Berg

CEO, AM-Pharma  Erik brings over 25 years’ experience and serves as CEO at AM-Pharma since 2011.  Erik is Chairman of Step Pharma and co-founder and previous (executive) Chairman of Lava Therapeutics (NASDAQ: LVTX), co-founder and previous (executive) Chairman of Heatmatrix Group (sold to BosNieuwkerk) and was board member of Lead

Read More >

Giuseppina Caligiuri, MD, PhD

Fellow in Cardiology, Research Associate  Giuseppina has a longstanding research experience in the role of CD31 in vascular biology and immunology. She works both as a cardiologist and a research scientist at the University Hospital Bichat, in Paris. Giuseppina completed her medical studies at the Catholic University of Rome, obtained

Read More >

Giuseppina Caligiuri, MD, PhD

Giuseppina has a longstanding research experience in the role of CD31 in vascular biology and immunology. She works both as a cardiologist and a research scientist at the University Hospital Bichat, in Paris. Giuseppina completed her medical studies at the Catholic University of Rome, obtained a PhD in experimental medicine

Read More >

Prof. Antonino Nicoletti, PhD

Professor and head of the doctoral school in Immunology at the University Paris Cité, Antonino leads the Laboratory for Vascular Translational Science, INSERM U1148, in Paris. Antonino Nicoletti obtained a PhD on inflammation in hypertension in Paris and performed a postdoc at the Karolinska Institute in Stockholm where he demonstrated

Read More >

Ximing Ding, PhD

Associate, Pureos Bioventures  At Pureos, Ximing is active in deal flow generation, investment due diligence, investment and exit transactions as well as fundraising support. In addition to Tridek-One, Ximing is currently BoD observer at Araris Biotech and Engimmune Therapeutics. He obtained his PhD at the European Molecular Biology Laboratory and

Read More >

Alexander Demoulin

Associate, Bioqube Ventures,   Alex joined Bioqube in 2016 as a member of the investment team. He is involved in the entire investment process for both portfolio investments and early stage venture creation as part of Bioqube’s dual investment model, from sourcing deals to advancing investment opportunities and performing due diligence. 

Read More >

Fraser Murray, PhD

Scientific Advisor, Advent Life Sciences   Fraser is a neuropharmacologist with almost 30 years of drug discovery and early development experience across a range of therapeutic areas, including neurodegeneration, psychiatry, inflammation, gastrointestinal and dermatology. He has a wide C-suite experience in multiple biotech startups and held leadership roles at Shire, AstraZeneca,

Read More >

Benoit Barteau, PhD

Investment Director, Life Sciences, Bpifrance Investissements  Since 2014 at Bpifrance Investissements, Benoit has been involved in a dozen investment deals and current board member positions include Alentis, Dynacure, Igyxos, Meiogenix and BrainEver. Prior to this, he gained experience in various biotech roles, co-discovered a vaccine candidate, and developed an antibody

Read More >

Klaus Breiner, PhD

Managing Partner, Pureos Bioventures  Over the last two decades, Dr. Breiner has invested in a broad range of life science companies. Before becoming a venture capitalist, he was a business consultant with Booz Allen & Hamilton in Zurich, and a researcher at the Swiss Federal Institute of Technology in Zurich and

Read More >

Alain Huriez, MD

Chairman and Managing Partner, AdBio Partners  Alain brings over 30 years of experience in life sciences and finance. He started his career as a General Practitioner (GP) and then spent ten years in biotechnology drug development and regulatory strategy as vice president of Quintiles (IQVIA) Europe. Prior to joining VC firm Advent Life Sciences

Read More >